Adenovirus (Ad) i-leader protein is a small protein of unknown function. The C-terminus truncation of the i-leader protein increases Ad release from infected cells and cytotoxicity. In the current study, we use the i-leader truncation to enhance the potency of an oncolytic Ad. In vitro, an i-leader truncated oncolytic Ad is released faster to the supernatant of infected cells, generates larger plaques, and is more cytotoxic in both human and Syrian hamster cell lines. In mice bearing human tumor xenografts, the i-leader truncation enhances oncolytic efficacy. However, in a Syrian hamster pancreatic tumor model, which is immunocompetent and less permissive to human Ad, antitumor efficacy is only observed when the i-leader truncated oncolytic Ad, but not the non-truncated version, is combined with gemcitabine. This synergistic effect observed in the Syrian hamster model was not seen in vitro or in immunodeficient mice bearing the same pancreatic hamster tumors, suggesting a role of the immune system in this synergism. These results highlight the interest of the i-leader C-terminus truncation because it enhances the antitumor potency of an oncolytic Ad and provides synergistic effects with gemcitabine in the presence of an immune competent system.
INTRODUCTION
Despite the promising use of oncolytic adenovirus (Ad) in cancer therapy, over 20 clinical trials with different oncolytic Ads by intravenous or intratumoral administration have shown good safety but modest efficacy. 1 One of the main barriers to oncolytic Ads efficacy is the virus spread through the tumor mass. 2 Several strategies have been proposed to enhance intratumoral spread: the use of ECM-degrading enzymes, enhancing permissivity of the virus to stromal cells and enhancing the cytotoxicity or the release of the virus from the infected cells. [3] [4] [5] After a bioselection of random mutants with enhanced cytotoxicity in cancer-associated fibroblasts, we previously identified the iLG397T i-leader C-terminal truncating mutation. 6 The iLG397T mutation enhanced Ad release in cancer-associated fibroblast and tumor cells, and apoptosis-independent cytotoxicity. In vivo, an Ad with the truncated i-leader disseminated better through the tumor, enhancing its antitumor efficacy, especially when tumors were embedded with human fibroblasts. 6 Similar i-leader truncated Ad mutants have been identified after bioselection in cancer cell lines. 7, 8 The convergence between different bioselection processes highlights the importance of the i-leader truncation for Ad potency.
For a virotherapeutic use, it is necessary to restrict virus replication to tumor cells. ICOVIR-15 is an oncolytic Ad that presents an appealing efficacy/toxicity ratio. To restrict its replication to tumor cells, it has the D24 deletion that abrogates E1A binding to pRb and the insertion of four palindromic E2F-binding sites and one Sp-1 binding site in the E1A endogenous promoter to control E1A-D24 transcription upon pRb deregulation.
Moreover, ICOVIR-15 has an RGD peptide inserted in the HI-loop that enhances the targeting to tumor cells. 9 Aiming at the generation of a more potent oncolytic Ad, we have introduced the iLG397T mutation into ICOVIR-15 to obtain ICOVIR-15i. We demonstrate that the iLG397T mutation maintains its phenotype in an E1A-transcriptionally regulated oncolytic Ad providing enhanced release, cytotoxicity and antitumor activity in vivo in a human lung adenocarcinoma xenograft tumor model.
To date, it is clear that accelerating virus release improves spreading through the tumor and antitumor activity in human tumor xenografts in immunodeficient mice. [10] [11] [12] However, Ad is highly immunogenic and studying the interactions with the immune system is critical for the application of Ads in the clinic. 13 This may be especially relevant for a fast-release Ad mutant, as it could induce higher immune responses than wild-type Ad. 5 Syrian hamsters have been proposed as an immunocompetent semi-permissive model to study the antitumor efficacy and toxicity of oncolytic Ads. 14, 15 To date, no significant differences in antitumor activity with fast-release mutants in this model have been shown. However, the Ads studied have their immunomodulatory functions compromised due to total or partial E3 deletions. 11, 16 In the present work, we study the role of i-leader truncation in the context of an oncolytic Ad that preserves all the E3 immune evasion functions, in an immunocompetent pancreatic cancer model in Syrian hamsters, alone or combined with gemcitabine. Gemcitabine shows synergy with several oncolytic Ad. [17] [18] [19] [20] In hamster, we found a synergistic effect of gemcitabine with the fast-release oncolytic Ad ICOVIR-15i. These results provide valuable data for the translation to the clinic of fast-release oncolytic Ads. 
MATERIALS AND METHODS

Cell lines
Human HEK293 and A549 lung adenocarcinoma cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). HP-1 Syrian hamster pancreatic tumor cell line was obtained from M Yamamoto (Minneapolis, MN, USA) with MA Hollingsworth (Nebraska, NE, USA) permission. All were maintained with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Invitrogen Carlsbad, CA, USA) and penicillin-streptomycin (PS, Gibco-BRL, Barcelona, Spain). All cell lines were routinely tested for mycoplasma contamination.
Recombinant Ad ICOVIR-15 has been previously described by our group. 9 pAdZ-ICOVIR-15i was generated by homologous recombination in bacteria 38 following a positive-negative selection method based on the RpsL-Neo cassette to substitute the wild-type i-leader for the truncated i-leader containing iLG397T mutation (G to T point-mutation in the 397 nucleotide of the i-leader sequence) in the pAdZ-ICOVIR-15 plasmid. The sequence containing the truncated i-leader was amplified by PCR from pAdR1 plasmid 6 with the primers Ad7131F (5 0 -GCGGTTGAGGACAAACTCT-3 0 ) and Ad8751R (5 0 -GCCCGTCGTCTTCACGCAG-3 0 ) (Sigma-Aldrich, Spruce St, St Louis, MO, USA). The resulting plasmid was transfected into HEK293 cells generating ICOVIR-15i. After transfection the virus was plaque-purified in A549 cells. All viruses were amplified in A549 cells and purified by cesium chloride gradients following standard protocols. Plasmids and viruses were sequenced to confirm the presence of all genetic modifications. Virus-containing cell extracts were functionally titered in TU ml À 1 (TU, transducing units) using an anti-hexon staining-based method. Purified viruses were physically titered by optical density at 260 nm in vp ml À 1 (vp, viral particles) and functionally titered by anti-hexon staining. The ratios between functional and physic titer were similar for the viruses used, 48.3 vp per TU for ICOVIR-15 and 76.87 vp per TU for ICOVIR-15i.
Plaque assay A549 cells seeded in six-well plates were infected with serial dilutions of the indicated viruses. Four hours after infection, the medium was removed and cells were covered with a 1:1 DMEM 5% FBS: 1% agarose mix. Once the agarose overlay solidified DMEM 5% FBS was added. To study the plaque size, after 7 days for A549 and 15 days for HP-1 cells, the plaque assays were stained by incubation with 0.5 mg ml À 1 thiazolyl blue tetrazolium bromide (MTT; Sigma-Aldrich, St Louis, MO, USA) at 37 1C and 5% CO 2 for 4 h. To isolate clones by plaque purification, after 7 days, the media was removed and single isolated plaques were picked with a filter tip and resuspended in 500 ml of DMEM 5% FBS.
In vitro cytotoxicity assays , plates were washed with phosphate-buffered saline (PBS) and stained for total protein content with BCA (bicinchoninic acid assay; Pierce Biotechnology, Rockford, IL, USA). Absorbance was quantified at 540 nm after 30 min of incubation. IC 50 value, equivalent to the virus dose required to produce 50% cell growth inhibition, was calculated from dose-response curves by standard nonlinear regression (GraFit; Erithacus Software, Horley, UK) using an adapted Hill equation. The two-tailed Student's t-test was used to study the statistical significance of the IC 50 differences between both viruses. For gemcitabine experiments, 1 Â 10 4 HP-1 cells were seeded in 96-well plates the day before the infection. Gemcitabine (Lilly S.A; Indianapolis, IN, USA) was added to a final concentration of 5 and 10 nM just after the infection and incubated for 11 days.
Virus release and production assays A549 and HP-1 cells seeded in 24-well plates were infected in triplicates with 20 TU per cell of the indicated virus to allow 80-100% infection. Four hours after infection, medium was removed, cells were washed three times with PBS, and incubated with fresh medium. At indicated time points samples of supernatant (SN, containing the released virus) and cell extract (CE, containing all media and cells representing the total amount of virus produced) were collected. Virus was quantified by an anti-hexon staining-based method in HEK293 cells. The two-tailed Student's t-test was used to evaluate the statistical significance of the difference in virus release and production between different viruses.
Evaluation of antitumor efficacy in vivo
In vivo studies were performed at the ICO-IDIBELL facility (Barcelona, Spain) AAALAC unit 1155, and approved by the IDIBELL's Ethical Committee for Animal Experimentation. Human lung carcinoma and Syrian hamster pancreatic tumors were established by subcutaneous injection of 2 Â 10 6 A549 cells or 4 Â 10 6 HP-1 cells, respectively, into the flanks of 8-week-old female BAlb/C nu/nu mice (Harlan, Indianapolis, IN, USA), and 1 Â 10 6 HP-1 cells into the flanks of 6-week-old female Golden Syrian hamsters (Janvier, Le Genest Saint Isle, France). When tumors reached 100-150 mm 3 (for mice) or 200 mm 3 (for Syrian hamsters) animals were randomized (n ¼ 12-14 tumors per group for mice and n ¼ 9-10 tumors per group for Syrian hamsters) and treated with a single intratumoral injection of PBS or 2 Â 10 9 vp per tumor for mice or 2.5 Â 10 10 vp per tumor for Syrian hamster of ICOVIR-15 or ICOVIR-15i in a total volume of 25 ml per tumor. For indicated experiments, 50 mg kg À 1 of gemcitabine at day 0, 3, 6 and 9 was administrated intraperitoneally. This dose is equivalent in mice to half the standard dose in humans. 39 Tumor size and animal weight were measured twice a week. Tumor volume and growth were calculated as previously. 9 The two-tailed Student's t-test was used to study the statistical significance of the differences in the tumor growth of the different treatment groups. For Kaplan-Meier survival curves, end point was established at a tumor volume X500 mm 3 for mice and X2000 mm 3 for Syrian hamster. Animals whose tumor size never reached the threshold were included as rightcensored information. A log-rank test was used to determine the statistical significance of the differences in time-to-event.
Immunohistofluorescence detection of adenoviral E1A protein in xenograft tumor OCT-embedded sections of the A549 xenograft tumors at the end of the efficacy experiment were incubated with anti-Ad-2/5 E1A (13S-5) SC-430 rabbit polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Alexa Fluor 488-labeled goat anti-rabbit IgG (Invitrogen Molecular Probes, Eugene, OR, USA) antibodies and counterstained with 4,6-diamino-2-phenylindole. Section images were obtained on an Olympus BX60 fluorescence microscope (Olympus America, Melville, NY, USA).
Lymphocyte proliferation assay
Peripheral blood mononuclear cells (PBMCs) from the hamsters treated with ICOVIR-15 or ICOVIR-15i alone or in combination with gemcitabine and the corresponding PBS controls were isolated by a standard ficoll gradient protocol. All PBMCs samples were diluted at 3 Â 10 6 cells per ml, labeled with carboxyfluorescein succinimidyl ester (CFSE), (Sigma-Aldrich, St Louis, MO, USA) at a final concentration of 10 mM, and exposed to target cells at 10:1 ratio during 5 days. Target cells were infected PBMCs, infected and non-infected HP-1 cells. PBMCs were infected at 200 TU per cell and HP-1 cells at 40 TU per cells with purified ICOVIR-15 for 3 h at 37 1C to ensure antigen presentation just before the exposure to CFSE-labeled PBMCs samples. As a positive control, we treated PBMCs with Concanavalin A at a final concentration of 5 mg ml À 1 . As a negative control we used non-stimulated PBMCs labeled with CFSE. After 5 days, the proliferation of the PBMCs was analyzed by flow cytometry; results are presented as cell division index. The cell division index was calculated according to the formula: percentage of CFSE diminished cells after antigen stimulation divided by percentage of CFSE diminished cells without stimulation, 40 where the percentage of CFSE diminished cells corresponds to the ratio of proliferating cells over the total number of cells. The Mann-Whitney test was used to evaluate the statistical significance of the difference in lymphocyte proliferation between each treatment.
RESULTS AND DISCUSSION
iLG397T i-leader truncating mutation enhances ICOVIR-15 plaque size, cytotoxicity and virus release in vitro To increase the potency of ICOVIR-15, the iLG397T i-leader truncating mutation 6 was inserted into its genome generating ICOVIR-15i. In A549 cells, a human lung carcinoma cell line highly permissive to Ad replication, ICOVIR-15i displayed large plaque phenotype, representative of an enhanced cell-to-cell spread iLG397T mutation enhances ICOVIR-15 plaque size and cytotoxicity in a Syrian hamster tumor model To characterize the effect of iLG397T mutation in an immunocompetent model, the phenotype of ICOVIR-15i was assessed in HP-1, a pancreatic carcinoma cell line from Syrian hamster. 21 In vitro, ICOVIR15i generated large plaques compared with ICOVIR-15 (Figure 3a) , and enhanced cytotoxicity with a statistically significant 15.7-fold decrease in the IC 50 (P ¼ 0.008) compared with ICOVIR-15 ( Figure 3b) . Although iLG397T mutation maintains its phenotype in this Syrian hamster cell line, the differences between both viruses were lower compared with the differences in human cells ( Figures  1a, b and c) . This could be explained by the lower permissiveness of this model compared with human cells (100-fold lower than in human A549 cells, data not shown). However, our results showed that HP-1 are more permissive to Ad replication than other hamster cell lines (such as HaPT-1, H2T or Amel-3; data not shown) and therefore, was selected in our studies. In contrast to the IC 50 cytotoxicity, experimental conditions that allowed only one replication round, such as the infection at high multiplicity of infection (M.O.I), did not show release or production advantages for ICOVIR15i compared with ICOVIR-15 (Figure 3c ), contrary to the results found in human cells (Figure 1c ). This suggests that several rounds of virus replication were needed in less permissive cells to maximize the differences between both viruses. iLG397T mutation combined with gemcitabine increases ICOVIR-15 antitumor activity in Syrian hamsters To further enhance the oncolytic potency of ICOVIR-15i in immunocompetent animal models, we combined it with gemcitabine. Gemcitabine has shown synergistic effects with different oncolytic Ad at clinical 22 and pre-clinical levels due to several mechanisms: (i) an E1A-induced sensitization of cancer cells to gemcitabine, 19, 23 (ii) increased infectivity due to coxsackievirusadenovirus receptor and integrin overexpression, 20, 23 (iii) activation of promoters that regulate replication of the oncolytic Ad, 19 and (iv) apoptosis activation when combined with E1b/ 19K-deleted mutants. 17, 18 However, depending on the timing before infection, nucleotide analogs such as gemcitabine could hamper viral DNA replication and cell lysis. 20 Another reason that supports the combination of the i-leader-truncated fast-release mutant with chemotherapy is that stroma blocks dissemination of chemotherapy drugs from blood vessels to the tumor cells. 24 Consequently, targeting tumor cells and cancer-associated fibroblast with ICOVIR-15i may not only improve the spread of the oncolytic virus, but also the penetration of the chemotherapeutic drugs. Conversely, chemotherapy can reduce the intratumoral interstitial pressure by killing tumor cells, and enhance the penetration of the virus into the tumor mass. 25 First, we studied the in vitro cytotoxicity of ICOVIR-15i and ICOVIR-15 combined with increasing doses of gemcitabine (always below its IC 50 value). In vitro, gemcitabine did not have a synergistic effect with the virus. On the contrary, ICOVIR-15i was as cytotoxic as ICOVIR-15 when combined with gemcitabine ( Figure 4a ). However, in hamsters bearing subcutaneous HP-1 tumors and treated with a single intratumoral dose of PBS, ICOVIR-15, or ICOVIR-15i at 2.5 Â 10 10 vp per tumor alone or in combination with a low dose of gemcitabine (a dose of 50 mg kg À 1 intraperitoneally at days 0, 3, 6 and 9 post virus administration), only the combination of ICOVIR-15i with gemcitabine resulted in antitumor activity (Figure 4b ). ICOVIR-15i/gemcitabine combination induced a 2.6-fold statistically significant decrease in the tumor growth compared with PBS, and an improvement in the mean survival time compared with other treatments, which increased from 29.9 days in the PBS group to 36.8 days (Figure 4c) . No activity was seen with ICOVIR-15 or ICOVIR-15i alone, gemcitabine alone, or the combination of ICOVIR-15 and gemcitabine. Virus replication in the tumors at the end of the experiment could not be detected in any of the treatment groups by immunofluorescent staining against E1A protein (data not i-leader truncated oncolytic adenovirus C Puig-Saus et al shown). The lower permissiveness of hamster cells compared with human cells tampered the iLG397T mutation phenotype in vitro and hindered it in vivo. The elimination of the virus by the immune system, independently of the i-leader truncation, may also have contributed to the lack of antitumor activity in hamsters, which precluded the observation of a phenotype related to the i-leader truncation when administered alone.
For a rational combination of gemcitabine and i-leader truncated oncolytic Ad, the mechanism relying on the antitumor activity in immunocompetent animals should be addressed. Emerging clinical and experimental data indicate that immunogenic cell death improves the response to cytotoxic agents recruiting mature, specific immune effector cells to the tumor. 26 Some of these cells have immunosuppressive functions and become dominant as the tumor is cleared by the cytotoxic response. Regulatory cells induce tissue remodeling and angiogenesis, but the incomplete eradication of malignant cells gives rise to tumor regrowth. 26 Moreover, gemcitabine enhances antigen presentation, and inhibits regulatory T cells, and immature myeloid cells. [27] [28] [29] [30] [31] Although most immunogenic cytotoxic compounds trigger a protective immune response, they fail to control the disease, therefore several adjuvants to increase immunogenic cell death and Th1 response could synergize with chemotherapies. 32 Oncolytic Ads induce a necrosis-like cell death, a release of HSP70 and HMBG1 (immunogenic cell death markers) 33 together with other immunostimulatory factors and generate a source of tumor-associated antigens available for cross-priming of dendritic cells, ensuring polyclonal T cell activation. [33] [34] [35] As a preliminary test of this immunogenic hypothesis we observed upon incubation with HP-1 cells, the highest lymphocyte proliferation in animals treated with the ICOVIR-15i/gemcitabine combination (Figure 4d ). Ad infection of HP-1 target cells did not change lymphocyte proliferation, and no significant lymphocyte proliferation was observed upon incubation with infected PBMCs, suggesting a specific immune response against HP-1 cells. In addition, we studied the antitumor efficacy of the ICOVIR-15i/ gemcitabine combination in xenografted HP-1 tumors in nude mice and confirmed that in the absence of immunity ICOVIR-15i/ gemcitabine had no antitumor activity (Supplementary Figure S1) . These results highlight the low permissivity of HP-1 cells to Ad replication, and suggest a role of the immune system behind the antitumor efficacy shown in the treatment with ICOVIR-15i/ gemcitabine in immunocompetent animals. Although we could not detect virus replication in the Syrian hamster tumors, we cannot exclude the role of ICOVIR-15i replication in Syrian hamster fibroblasts in the observed antitumor efficacy.
Supporting this immune-mediated hypothesis, Boozari and coworkers described a combination of an oncolytic Ad with a proteasome inhibitor that caused endoplasmic reticulum stressinduced apoptosis responsible for triggering immunogenic cell death. This immunogenic cell death induced a potent antitumor immune response capable of controlling the primary tumors and also the non-injected metastasis. 36 It is intriguing to speculate whether the iLG397T mutation in particular, or the fast-release mutations in general, in combination with gemcitabine induce a more immunogenic cell death.
Our results highlight the interest of the i-leader truncation in particular, and the fast-release mutants in general, to improve the potency of oncolytic Ads, and support the combination of fastrelease mutants with chemotherapeutic drugs for cancer treatment. Studying the combination of i-leader truncated oncolytic mutants with different chemotherapeutic drugs with higher capacity to suppress regulatory cells 37 or induce immunogenic cell death is warranted.
